search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Outsourcing


Central laboratories have become an important part of running global clinical trials in Europe and the US. With the rapid increase in the number of studies conducted in China and other Asia-Pacifi c countries, sponsors should understand how to choose central labs in these regions too. Kim Thomas asks Honggang Bi, senior vice-president and head of APAC at Labcorp Drug Development, and Michael W Young, principal at biomedwoRx: Life Sciences Consulting, what sponsors should look for when outsourcing to a central lab.


central lab Choosing the right


I 34


n the past few decades, China and other Asia- Pacific countries have become popular locations for clinical trials. The trend towards holding studies in the region doesn’t appear to be slowing down either, with analysts estimating that the current $7.6bn contract research organisation market will grow to $11.9bn by 2025. That popularity has been at least partly driven by the relatively low market rates of the clinical trial workforce. Some of the costs can be 25–35% lower than they are in the US and some European countries, says Michael W Young, a principal at


biomedwoRx: Life Sciences Consulting. This is particularly the case, he says, in the areas of “data management, biostatistics and central lab testing, including bioanalytics”.


Another consideration is that if a drug is designed to be used for a condition that affects a particular ethnic population, it makes sense to have that population well represented in trials. Regulatory bodies, says Honggang Bi, head of APAC at Labcorp Drug Development, “may require populations from their own region to be included in the trial so they can review the data with better confidence”.


Clinical Trials Insight / www.worldpharmaceuticals.net


ImagingStocker/Shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45